Jesús María Hernández-Rivas

Universidad de Salamanca

Research Interests

Explore related searches

Contact this professor

Google Scholar

Articles (20)

Collaborators (21)

María Díez Campelo

Universidad de Salamanca

ROSA MARIA AYALA DIAZ

Full Professor

Universidad Complutense de Madrid

Emiliano Rodriguez-Sanchez

Associate professor

Universidad de Salamanca

Julio Delgado

Hospital Clínic de Barcelona

María Hernández-Sánchez

Profesor Ayudante Doctor

Universidad Complutense de Madrid Facultad de Medicina

Frederik Damm

Charité - Universitätsmedizin Berlin

Ignacio García-Tuñón Llanio

Profesor Ayudante Doctor

Universidad de Alcalá

Oscar Molina

PABLO VELASCO

Department Associate Professor

University of Barcelona

José Rivera

Peter Mol

Professor Drug Regulatory Science

University Medical Center Groningen

José María Bastida

Josep Maria Ribera Santasusana

Chief of the Department

Institut Català d'Oncologia

M ROCIO BENITO SANCHEZ

Universidad de Salamanca

Maria Teresa VOSO

Professore Ordinario di Ematologia

Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia

Professor Jonathan C Strefford

Professor of Molecular Oncology

University of Southampton

UNITED KINGDOM

Bob Löwenberg

Thomas Pabst

Francesco Cerisoli

Head of Research

Pedro Cunha

Invited Professor / Researcher

University of Minho

Lars Bullinger

Charité University Medicine

Jesús María Hernández-Rivas

Research Interests

Explore related searches

Contact this professor

Articles (20)

Examining the Effects of the RUNX1 p.Leu43Ser Variant on FPD/AML Phenotypes Using a CRISPR/Cas9-Generated Knock-In Murine Model

Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial

Optimizing Patient Registries for Regulatory Decision Making ‐ Key Learnings From an <scp>HMA</scp>/<scp>EMA</scp> Multistakeholder Workshop

SAMHD1 dysfunction impairs DNA damage response and increases sensitivity to PARP inhibition in chronic lymphocytic leukemia

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.

Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia

Sex Differences in Gut Microbiota and Their Relation to Arterial Stiffness (MIVAS Study)

A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

CRISPR/Cas9-Directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CML

A novel nonsense variant in TPM4 caused dominant macrothrombocytopenia, mild bleeding tendency and disrupted cytoskeleton remodeling.

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia.

ALL-268 Genetic Classification of B-Cell Precursor Adult Acute Lymphoblastic Leukemia Patients Enrolled in LAL19 Trial from the Pethema Group: Response to Treatment and Survival

Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

MDS-454 SF3B1 and DNMT3A Mutations Might Play a Role in Poor Prognosis and AML Progression in Patients With Isolated del(5q) MDS

Collaborators (21)

María Díez Campelo

ROSA MARIA AYALA DIAZ

Emiliano Rodriguez-Sanchez

Julio Delgado

María Hernández-Sánchez

Frederik Damm

Ignacio García-Tuñón Llanio

Oscar Molina

PABLO VELASCO

José Rivera

Peter Mol

José María Bastida

Josep Maria Ribera Santasusana

M ROCIO BENITO SANCHEZ

Maria Teresa VOSO

Professor Jonathan C Strefford

Bob Löwenberg

Thomas Pabst

Francesco Cerisoli

Pedro Cunha

Lars Bullinger

How do I reach out?

Meet Kite AI